Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Popular GLP-1 medications include semaglutide and tirzepatide, which have helped many individuals achieve meaningful weight loss when combined with healthy lifestyle changes
Seven additional Phase 3 readouts expected throughout 2026 (including general obesity, type 2 diabetes, CV/kidney outcomes, sleep apnea, low back pain, etc.)
It plays a key role in how the body regulates hunger - slowing stomach emptying, signaling fullness to the brain, and helping stabilize blood sugar between meals
)
Individual results vary depending on treatment duration, medical history, and adherence to the prescribed plan
Higher doses of any GLP-1 medication, which produce faster weight loss, may increase telogen effluvium likelihood
How often it happens The rates vary by trial and population: 2,3 TRIUMPH-4 (obesity with knee osteoarthritis): 8.8% on 9 mg, 20.9% on 12 mg, 0.7% on placebo TRANSCEND-T2D-1 (type 2 diabetes): 4.5% on 4 mg, 2.3% on 9 mg, 4.4% on 12 mg, 0% on placebo Phase 2 trial (Jastreboff 2023): not reported The TRIUMPH-4 numbers are markedly higher than those of TRANSCEND-T2D-1
US$ 26.84
US$ 22.08
US$ 29.38
US$ 22.13
US$ 26.27
US$ 23.22
US$ 20.54
